We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognotic impact of serum follistatin in patients with hepatocellular carcinoma.
- Authors
Tomoda, Takeshi; Nouso, Kazuhiro; Miyahara, Koji; Kobayashi, Sayo; Kinugasa, Hideaki; Toyosawa, Junki; Hagihara, Hiroaki; Kuwaki, Kenji; Onishi, Hideki; Nakamura, Shinichiro; Ikeda, Fusao; Miyake, Yasuhiro; Shiraha, Hidenori; Takaki, Akinobu; Yamamoto, Kazuhide
- Abstract
Background and Aim Follistatin ( FST) is a glycoprotein expressed in most organs, which interacts with activins or other members of the transforming growth factor beta family. Recently, several reports have shown that FST regulates a variety of processes during tumor progression. Here, serum FST in patients with liver diseases was measured, and its clinical utility as a biomarker was assessed. Methods Serum was collected from 162 patients (91 hepatocellular carcinoma [ HCC], 43 liver cirrhosis, and 28 chronic hepatitis) as well as from 16 healthy volunteers. FST was quantified by enzyme-linked immunosorbent assays, and levels were compared with clinical parameters including survival of the HCC patients. Results Median serum FST levels in HCC, liver cirrhosis, chronic hepatitis, and healthy volunteers were 1168, 1606, 1324, and 1661 pg/m L, respectively, not significantly different. In HCC patients, higher serum FST was associated with greater age, hepatitis C virus antibody-negativity, large tumor size, g-glutamyl transpeptidase, des-gamma carboxyprothrombin and presence of portal vein tumor thrombus. Survival of HCC patients with high FST levels was significantly shorter than for those with low levels ( P = 0.004). Multivariate analysis revealed that in addition to large tumor size and presence of portal vein thrombus, high FST levels were independently correlated with poor prognosis (hazard ratio = 2.41, 95% confidence interval = 1.16-5.00, P = 0.02). Conclusions Serum FST levels are significantly associated with HCC prognosis and could represent a predictive biomarker in this disease.
- Subjects
FOLLISTATIN; GLYCOPROTEINS; BLOOD plasma; TRANSFORMING growth factors; LIVER cancer
- Publication
Journal of Gastroenterology & Hepatology, 2013, Vol 28, Issue 8, p1391
- ISSN
0815-9319
- Publication type
Article
- DOI
10.1111/jgh.12167